Keythera (Suzhou) Biopharmaceuticals is a clinical-stage biotech building first-in-class small molecule drugs for cancer and autoimmune disease. Its core edge is ADMS - Affinity Detection by Mass Spectroscopy - an affinity-based high-throughput screening platform that can screen up to 250,000 compounds per day per workstation and fuses bioinformatics, structural chemistry, computer-aided drug design and AI to find and optimize drug candidates faster and at lower risk. Founded in 2020 by industry veteran Dr. Yongqi Deng, the company has built six pipelines, advanced its lead EP4 antagonist KF-0210 into the clinic, and raised roughly RMB 100M in Series A funding.
Mirador Therapeutics is a San Diego precision-medicine company building first- and best-in-class therapies for immune-mediated inflammatory and fibrotic diseases. Its Mirador360 engine fuses human genetics, multi-modal patient data, AI and advanced analytics to find novel targets, design combination therapies and identify the patients most likely to respond. Founded in 2024 by the former Prometheus Biosciences leadership team, Mirador launched with more than $400 million and has since raised over $650 million total.
Paradigm4 builds scientific data management and analytics software for the life sciences. Its flagship REVEAL platform and SciDB array database let pharma, biotech, and research institutions integrate and analyze massive multimodal datasets - genomics, multi-omics, imaging, clinical records, wearables, and environmental data - to find biomarkers and validate drug targets. Co-founded in 2010 by entrepreneur Marilyn Matz and Turing Award-winning MIT professor Michael Stonebraker, the company is based in Waltham, Massachusetts.
Totus Medicines is a clinical-stage precision medicines company in Emeryville, California, building covalent small-molecule drugs against historically undruggable targets. Its AI-powered OmniDEL platform screens billions of DNA-encoded covalent candidates against thousands of targets inside living cells, surfacing molecules that older methods miss. Its lead program, TOS-358, is the first and only covalent PI3Ka inhibitor in clinical development, showing class-leading tolerability and strong disease control in breast, endometrial, and head & neck cancers.
Watershed Bio (legally Watershed Informatics) is a Cambridge, Massachusetts startup building a unified, cloud-based platform for biological data analysis. Its product, Omics Bench, lets biologists and bioinformaticians securely store, harmonize, and analyze multi-omic data - genomics, single-cell and spatial transcriptomics, epigenomics, proteomics, metabolomics, microbial sequencing and protein folding - using customizable and AI-assisted workflows backed by elastic supercomputing. The pitch: go from sample to therapeutic insight in a single day instead of weeks, closing the gap between high-code and no-code bioinformatics for drug-discovery teams.
Peter DiLaura is the CEO and Board Director of Helicore Biopharma, a San Mateo biotech building long-acting antibody-peptide conjugates that go after obesity by neutralizing the GIP hormone in the bloodstream rather than blocking its receptor. With nearly three decades of company-building behind him - CEO roles at Initial Therapeutics and Second Genome, business and strategy chief at Sonoma Biotherapeutics, and time as an Entrepreneur-in-Residence at Third Rock Ventures - he is the operator brought in to turn a $65M Series A and a clinic-ready antibody into medicines that aim for quarterly dosing and better-quality weight loss.
Excelsior Sciences is a New York City biotech building 'machine-native chemistry' - a way to make small molecules that machines can execute and AI can learn from. Its proprietary smart bloccs platform turns drug synthesis into a modular, automation-friendly, iterative process, closing the loop between AI-driven discovery and real-world manufacturing. Founded in 2024 and spun out of Deerfield Management, the company raised $95M in late 2025 to scale the platform and reshore U.S. drug discovery and production.
Inductive Bio is a New York-based AI company building a machine learning platform that predicts how small-molecule drugs will behave in the body before they are ever synthesized. By training models on a pre-competitive data consortium shared across biopharma teams, its Beacon models, Compass software, and Indy chemistry assistant help medicinal chemists nominate better development candidates faster - reducing the costly 'whack-a-mole' of balancing potency against ADMET properties in preclinical drug discovery.
Leal Therapeutics is a Worcester, Massachusetts biotech founded in 2021 by repeat CNS entrepreneur Asa Abeliovich, the scientist behind Prevail Therapeutics (acquired by Eli Lilly). Leal builds first-in-class neuro-metabolic medicines on a single idea: many brain diseases share a broken metabolism, and correcting those imbalances can treat conditions from schizophrenia to ALS. Backed by roughly $114M in total funding, its pipeline includes LTX-001, a brain-penetrant oral glutaminase inhibitor in the clinic, and LTX-002, an antisense oligonucleotide for ALS.
Myricx Bio is a London-based oncology biotech developing a completely new class of payloads for antibody-drug conjugates (ADCs), built on inhibitors of N-myristoyltransferase (NMT). Spun out of Imperial College London and the Francis Crick Institute, the company aims to give ADCs a fresh way to kill cancer cells that resist today's standard payloads. In July 2024 it closed a £90m ($114m) Series A, one of Europe's largest biotech rounds that year, to push its NMTi-ADC pipeline toward clinical trials.
Russell Beckerman is a biotech entrepreneur and Co-Founder & CEO of Overture Therapeutics, a Cambridge-based company engineering precision antibody medicines targeting obesity and metabolic dysfunction. He previously co-founded 82VS, a venture studio embedded within Alloy Therapeutics that has launched nine drug companies since 2020. His work sits at the intersection of cutting-edge antibody biology, company creation, and the conviction that the next generation of obesity drugs will be antibodies - not peptides.
Mohit Rawat is the Boston-based CEO of Myricx Bio, a UK-US biotech building a first-in-class antibody-drug conjugate platform based on NMT inhibition to treat cancer. He arrived in September 2025 fresh off Fusion Pharmaceuticals' $2.4 billion sale to AstraZeneca, where he was President and Chief Business Officer. With a Harvard MBA, an MIT chemical engineering master's, and stints at Novartis, AbbVie and McKinsey, he is steering Myricx toward its first human clinical trials in 2026.
Benchling is a cloud platform built for biotech R&D - a single, biology-first system of record where scientists design experiments, track samples, manage molecular data, and collaborate. Founded in 2012 out of MIT, it has grown into the operating system for modern life science, used by hundreds of thousands of scientists at companies ranging from startups to the largest biopharma firms, and is now embedding AI agents and predictive models directly into the lab workflow.
Ceremorphic is a San Jose-based fabless semiconductor startup building energy-efficient AI supercomputing silicon. Founded in 2020 by serial entrepreneur Venkat Mattela, the company taped out a first-of-its-kind 5nm HPC/AI chip on TSMC's most advanced node and is applying the same Hierarchical Learning Processor architecture to data center AI, robotics, automotive, and analog-AI-driven drug discovery.
Elucidata is a TechBio company building Polly, a data-centric ML-Ops platform that harmonizes messy biomedical data into AI-ready datasets for pharma R&D. Founded in 2015 by Abhishek Jha and Swetabh Pathak, the company powers drug discovery work at Pfizer, Genentech, Janssen and dozens of biotechs from offices in San Francisco, Boston and Delhi.
Abhishek Jha is the Co-Founder and CEO of Elucidata, a San Francisco-based AI company making biomedical data AI-ready for drug discovery and pharmaceutical R&D. A trained physical chemist with a PhD from the University of Chicago and postdoctoral work at MIT, he spent years at Agios Pharmaceuticals contributing to four FDA-approved first-in-class therapies before co-founding Elucidata in 2015. Under his leadership, the company has raised over $22.7M in funding, grown to 170 employees, and achieved $22.2M ARR, while evolving from a data-curation platform into an AI company solving out-of-distribution (OOD) problems in biomedical research - work that earned Elucidata recognition as one of Fast Company's Most Innovative Companies in 2024.
Maxim (Max) Kholin is the co-founder and COO of Gero, a physics-powered longevity biotech company applying statistical physics and AI to crack the biology of aging. With roots in contract law, international business, and computational drug design, he bridges the gap between cutting-edge science and real-world commercialization. Gero - which he co-founded with physicist Peter Fedichev in 2015 - has pioneered the field of 'Gerophysics,' trained its models on 100M+ longitudinal medical records, and secured partnerships with Pfizer and Chugai Pharmaceutical worth up to $250M in milestones. Based across Singapore and Palo Alto, Kholin's mission is nothing less than transforming humans into a non-aging species.
Peter Fedichev is a theoretical physicist turned longevity entrepreneur who co-founded Gero, a biotech AI company applying physics-based generative AI models to crack the root causes of aging. A former top-2 cited Russian physicist under 35, he traded quantum gases for aging clocks, building a platform that predicted biological age from wearable data before it was fashionable, secured a Pfizer collaboration, and landed a potential $250M deal with Chugai Pharmaceutical (Roche Group) in 2025 - all while publishing over 75 scientific papers and winning a $10,000 prize for winning a public debate on defeating aging.
Dr. Venkat Mattela is the Founder and CEO of Ceremorphic, Inc., a San Jose-based deep-tech company designing ultra-low-power AI supercomputing chips built on TSMC's 5nm process. A serial entrepreneur with a PhD in Electrical Engineering, he previously founded Redpine Signals and sold its wireless connectivity division to Silicon Labs for $308 million in 2020. With over 100 patents and four decades in semiconductor engineering, Mattela is now betting Ceremorphic's proprietary ThreadArch architecture can reshape AI computing for data centers, drug discovery, and next-generation HPC workloads.
Abdera Therapeutics is a precision oncology biotech engineering antibody-based radiopharmaceuticals that deliver therapeutic radioisotopes directly to tumor cells while sparing healthy tissue. Built around its proprietary ROVEr platform, the company is advancing ABD-147 in Phase 1 trials for small cell lung cancer and large cell neuroendocrine carcinoma, with a second program, ABD-320, on deck.
BigHat Biosciences is a San Mateo biotech using machine learning and a high-speed wet lab to design safer, more effective therapeutic antibodies. Its Milliner platform iterates between in-silico design and physical molecules in days, optimizing biologics across binding, stability, immunogenicity and developability for partners like Merck and Johnson & Johnson.
Frontier Medicines is a precision-medicine biotech using chemoproteomics, covalent chemistry, and machine learning to drug proteins long considered 'undruggable.' Its lead candidate, FMC-376, is a first-in-class dual ON/OFF inhibitor of KRAS G12C now in the Phase 1/2 PROSPER trial. Backed by $315M+ in venture funding and a major AbbVie partnership, the company is one of the most-watched names in next-generation targeted cancer therapy.
Profluent is an AI-first protein design company building frontier models that author novel proteins - including the first AI-designed CRISPR gene editor, OpenCRISPR-1. Based in Berkeley's biotech corridor, the company applies the same scaling-law playbook that worked for language models to the language of biology, then validates the outputs in a wet lab.
Dinesh V. Patel, Ph.D. is the President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), a Newark, California-based biopharmaceutical company he has led since December 2008. With over 38 years spanning medicinal chemistry, drug discovery, venture capital co-founding, and three CEO stints, Patel has guided Protagonist from a peptide-platform startup to a company with its first FDA-approved drug - ICOTYDE (icotrokinra), approved March 2026 as the world's first targeted oral peptide for moderate-to-severe plaque psoriasis, partnered with Johnson & Johnson.
Arthur T. Sands, M.D., Ph.D., is the President and CEO of Nurix Therapeutics, a clinical-stage biopharmaceutical company pioneering targeted protein degradation medicines. A co-founder of Lexicon Pharmaceuticals in 1995, he spent 19 years transforming that company from a research startup into a drug-development enterprise generating over $450 million in revenue. At Nurix, he leads efforts to deploy a proprietary DEL-AI platform - combining DNA-encoded libraries with machine learning - to discover and develop small-molecule degraders and degrader-antibody conjugates for cancer and inflammatory diseases. The company's lead asset, bexobrutideg (a BTK degrader), entered pivotal Phase 2 development in 2025 with an 83% objective response rate in relapsed CLL patients.
Joe Belanoff is the co-founder and CEO of Corcept Therapeutics, a Redwood City-based biopharmaceutical company he has led since 1999. A physician-scientist trained at Amherst College, Columbia University, and Stanford, Belanoff pivoted from academia to entrepreneurship after co-developing intellectual property on cortisol modulation with Stanford psychiatry chair Alan Schatzberg. Under his leadership, Corcept achieved two landmark FDA approvals: Korlym in 2012 for Cushing's syndrome and Lifyorli in 2026 for platinum-resistant ovarian cancer - the first selective glucocorticoid receptor antagonist ever approved. He maintains an adjunct professorship at Stanford while steering a company with over $760 million in annual revenue and more than 30 ongoing clinical studies.
Margo Georgiadis is CEO-Partner at Flagship Pioneering and co-founder & CEO of Montai Therapeutics, a biotech company using AI to discover drugs from natural compounds humans have consumed for centuries. A Harvard double-alumna (Phi Beta Kappa undergrad, Baker Scholar MBA), she has reinvented herself across industries - from McKinsey partner to Google Americas President, Mattel CEO, Ancestry.com CEO (overseeing its $5B sale to Blackstone), and now biotech pioneer building a platform that turns ancient botanicals and foods into precision medicines for chronic disease.
Dee Datta, Ph.D., is co-founder and CEO of Switch Therapeutics, a San Francisco-based biotechnology company pioneering conditionally activated siRNA (CASi) molecules to treat neurodegenerative diseases and other conditions with significant unmet need. With a PhD from Caltech, an MBA from Stanford, and a career spanning venture capital at The Column Group and Longitude Capital, corporate development at Forty Seven Inc., and the C-suite at XOMA, Datta brings rare scientific depth and dealmaking fluency to one of the most ambitious RNA medicine platforms in the field. Switch raised a $52 million Series A in March 2023 and in late 2024 named its first development candidate - CASi-APOE, a brain-targeted, liver-sparing RNAi therapy aimed at the 60% of Alzheimer's patients who carry the APOE4 gene variant.
Elaine Cheung is Chief Business Officer at Moonwalk Biosciences, a South San Francisco biotech backed by $57 million in funding and co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis. With 20+ years navigating the inflection points of genomic medicine - from spinning GRAIL out of Illumina, helping architect its $900M+ Series B, and steering Lyell Immunopharma through its IPO - Cheung brings a rare combination of scientific literacy and deal-making precision. At Moonwalk, she is helping build the business infrastructure for a company that has pivoted from epigenetic editing to siRNA-based therapeutics targeting adipose biology and obesity.
Eric Green is the Founder and CEO of Trace Neuroscience, a South San Francisco biotech company racing to develop the first effective ASO therapy for ALS. A Harvard-and-Stanford-trained physician-scientist with a background in cardiology, Green co-founded iLab Solutions (acquired by Agilent), Respira Design (Stanford $50K Challenge winner), and Maze Therapeutics before launching Trace with a $101 million Series A in November 2024. Trace's lead program targets UNC13A - a protein lost in ALS patients - using an antisense oligonucleotide designed to restore healthy nerve-muscle communication. With clinical trials targeting early 2026, Green is betting human genetics can do for ALS what it did for heart failure.